AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 99 filers reported holding AKERO THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $119,792,559 | +8.3% | 2,368,378 | 0.0% | 0.69% | +7.8% |
| Q2 2023 | $110,579,569 | +22.0% | 2,368,378 | 0.0% | 0.64% | +29.8% |
| Q1 2023 | $90,614,142 | -30.2% | 2,368,378 | 0.0% | 0.49% | -36.7% |
| Q4 2022 | $129,787,114 | +60.9% | 2,368,378 | 0.0% | 0.78% | +47.5% |
| Q3 2022 | $80,643,000 | +7106.7% | 2,368,378 | +1900.7% | 0.53% | +8700.0% |
| Q2 2022 | $1,119,000 | -33.4% | 118,378 | 0.0% | 0.01% | -40.0% |
| Q1 2022 | $1,680,000 | -32.9% | 118,378 | 0.0% | 0.01% | -16.7% |
| Q4 2021 | $2,504,000 | -5.4% | 118,378 | 0.0% | 0.01% | 0.0% |
| Q3 2021 | $2,646,000 | -9.9% | 118,378 | 0.0% | 0.01% | -7.7% |
| Q2 2021 | $2,937,000 | -14.5% | 118,378 | 0.0% | 0.01% | -13.3% |
| Q1 2021 | $3,434,000 | +12.4% | 118,378 | 0.0% | 0.02% | +25.0% |
| Q4 2020 | $3,054,000 | -24.7% | 118,378 | -10.2% | 0.01% | -25.0% |
| Q3 2020 | $4,058,000 | – | 131,788 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Skorpios Trust | 4,907,829 | $103,801,000 | 22.97% |
| venBio Partners LLC | 2,171,664 | $45,931,000 | 8.28% |
| Versant Venture Management, LLC | 617,727 | $13,065,000 | 6.99% |
| Atlas Venture Life Science Advisors, LLC | 2,232,251 | $47,212,000 | 4.34% |
| Yiheng Capital Management, L.P. | 1,551,090 | $32,806,000 | 1.67% |
| Redmile Group, LLC | 1,602,285 | $33,888,000 | 0.77% |
| Boxer Capital, LLC | 831,495 | $17,586,000 | 0.68% |
| Cormorant Asset Management, LP | 403,787 | $8,540,000 | 0.51% |
| Integral Health Asset Management, LLC | 85,000 | $1,798,000 | 0.50% |
| HHLR ADVISORS, LTD. | 1,359,152 | $28,746,000 | 0.44% |